In the last decades, emerging molecular targets for ischemic neuroprotection and regeneration have been postulated.
This fact allowed that classical drugs with well established therapeutic applications might be used in cerebrovascular
diseases as well as neurodegenerative diseases. Minocycline is a commonly used antibiotic of the tetracycline family
(7-dimethylamino-6-dimethyl-6-deoxytetracycline) which reveals cytoprotective capability and potential use in treatment
of different diseases. Here, we discuss the literature concerning minocycline. The available data indicate that the antibiotic
has multi-faceted effects on cell functions and, consequently, a number of clinical properties that are useful and/or could
be useful for treatment of different diseases including bacterial infections, cancer, autoimmune disorders, ischemia as well
as neurodegenerative and psychiatric diseases. Thus, application of minocycline as a therapeutic agent is the subject of
clinical trials for various diseases. It is also evident that minocycline-mediated cytoprotection, including neuroprotection,
is an important aspect of its clinical application. Here, we have reviewed the basis of the minocycline activity as well as
different studies indicating that minocycline can be used as potential therapeutic agent in both cerebrovascular and neurodegenerative
diseases in human.
Keywords: Cell death pathways, minocycline, cytoprotection, mitochondria, energy coupling, VDAC
Rights & PermissionsPrintExport